Ignite Creation Date:
2025-12-25 @ 12:29 AM
Ignite Modification Date:
2026-02-26 @ 12:41 AM
Study NCT ID:
NCT04178967
Status:
COMPLETED
Last Update Posted:
2023-05-24
First Post:
2019-11-25
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
Sponsor:
Eli Lilly and Company
Organization: